{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T10:21:01Z","timestamp":1756635661758,"version":"3.40.5"},"reference-count":40,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To investigate the risk of cutaneous herpes zoster (HZ) in spondyloarthritis (SpA) compared with that in rheumatoid arthritis (RA), and in disease\u2010modifying antirheumatic drugs (DMARDs) used in SpA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A total of 727 patients with an expert diagnosis of SpA were identified retrospectively from four rheumatology centers in Hong Kong. Electronic medical records from 1995 to 2018 were reviewed for incidence of cutaneous HZ and demographic data including age, sex, comorbidities, smoking and drinking status. DMARDs used included sulphasalazine, methotrexate, leflunomide, steroids, etanercept, infliximab, adalimumab, golimumab, secukinumab and ustekinumab. Cox regression models were used to evaluate hazard ratios (HRs) of different DMARDs in patients with SpA. Propensity score was used for matching and comparison with 857 patients with RA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 23 cases of cutaneous HZ in patients with SpA and 59 cases in patients with RA. Among patients with SpA, 7 cases of cutaneous HZ may be attributed to sulfasalazine treatment, 7 to methotrexate, 2 to leflunomide, 2 to infliximab, 1 to etanercept, 2 to adalimumab, and 1 to secukinumab. Risks of cutaneous HZ were the same in SpA (stratified HR 0.97; 95% CI 0.58; 1.61; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.89) and RA. Methotrexate (adjusted HR 3.47; 95% CI 1.25; 9.63; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.02) and infliximab (adjusted HR 10.67; 95% CI 1.37; 82.88; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.02) were found to be associated with HZ after adjustments for traditional risk factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Risk of cutaneous HZ in SpA was not lower than in RA. Methotrexate and infliximab were associated with cutaneous HZ in SpA.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.13694","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T08:53:47Z","timestamp":1567760027000},"page":"189-196","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Risk of cutaneous herpes zoster in patients with spondyloarthritis treated with conventional and biologic disease\u2010modifying antirheumatic drugs"],"prefix":"10.1111","volume":"23","author":[{"given":"Sabrina Ching Tung","family":"Wong","sequence":"first","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology The University of Hong Kong Hong Kong China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris Wai Sum","family":"Li","sequence":"additional","affiliation":[{"name":"School of Public Health The University of Hong Kong Hong Kong China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra Hoi Yan","family":"Ng","sequence":"additional","affiliation":[{"name":"Division of Rheumatology Caritas Medical Center Hong Kong China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chak Sing","family":"Lau","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology The University of Hong Kong Hong Kong China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0175-1346","authenticated-orcid":false,"given":"Ho Yin","family":"Chung","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology The University of Hong Kong Hong Kong China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_7_2_1","DOI":"10.1056\/NEJM200003023420906"},{"doi-asserted-by":"publisher","key":"e_1_2_7_3_1","DOI":"10.4065\/84.3.274"},{"doi-asserted-by":"publisher","key":"e_1_2_7_4_1","DOI":"10.1056\/NEJMcp1302674"},{"doi-asserted-by":"publisher","key":"e_1_2_7_5_1","DOI":"10.1002\/art.23112"},{"doi-asserted-by":"publisher","key":"e_1_2_7_6_1","DOI":"10.1093\/rheumatology\/kel328"},{"doi-asserted-by":"publisher","key":"e_1_2_7_7_1","DOI":"10.1002\/acr.22470"},{"doi-asserted-by":"publisher","key":"e_1_2_7_8_1","DOI":"10.1136\/bmj.g2911"},{"doi-asserted-by":"publisher","key":"e_1_2_7_9_1","DOI":"10.1080\/14397595.2017.1325034"},{"doi-asserted-by":"publisher","key":"e_1_2_7_10_1","DOI":"10.1007\/s11908-013-0356-y"},{"volume-title":"Propensity score analysis: statistical methods and applications. Advanced quantitative techniques in the social sciences series","year":"2010","author":"Guo S","key":"e_1_2_7_11_1"},{"doi-asserted-by":"publisher","key":"e_1_2_7_12_1","DOI":"10.1136\/bmjopen-2014-004833"},{"doi-asserted-by":"publisher","key":"e_1_2_7_13_1","DOI":"10.1017\/S0950268815000655"},{"doi-asserted-by":"publisher","key":"e_1_2_7_14_1","DOI":"10.1016\/S1473-3099(03)00857-0"},{"doi-asserted-by":"publisher","key":"e_1_2_7_15_1","DOI":"10.1186\/s12879-015-0747-9"},{"unstructured":"Hong Kong Statistics Census and Statistics Department.www.censtatd.gov.hk\/hkstat","key":"e_1_2_7_16_1"},{"issue":"5","key":"e_1_2_7_17_1","first-page":"171","article-title":"Sulfasalazine in the treatment of ankylosing spondylitis","volume":"112","author":"Krajnc I","year":"1990","journal-title":"Lijec Vjesn"},{"issue":"1","key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5152\/eurjrheum.2017.1608","article-title":"Real\u2010life experience of using conventional disease\u2010modifying anti\u2010rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine and leflunomide in PsA in comparison to spondyloarthritides other than PsA and literature review of the use of conventional DMARDs in PsA","volume":"4","author":"Roussou E","year":"2017","journal-title":"Eur J Rheumatol"},{"doi-asserted-by":"publisher","key":"e_1_2_7_19_1","DOI":"10.1002\/art.39670"},{"doi-asserted-by":"publisher","key":"e_1_2_7_20_1","DOI":"10.1186\/s12879-017-2198-y"},{"doi-asserted-by":"publisher","key":"e_1_2_7_21_1","DOI":"10.1111\/1756-185X.13650"},{"doi-asserted-by":"publisher","key":"e_1_2_7_22_1","DOI":"10.1136\/annrheumdis-2016-210770"},{"doi-asserted-by":"publisher","key":"e_1_2_7_23_1","DOI":"10.1093\/ofid\/ofw205"},{"doi-asserted-by":"publisher","key":"e_1_2_7_24_1","DOI":"10.1111\/1756-185X.13300"},{"doi-asserted-by":"publisher","key":"e_1_2_7_25_1","DOI":"10.1016\/0002-9343(91)80008-A"},{"doi-asserted-by":"publisher","key":"e_1_2_7_26_1","DOI":"10.1001\/jama.2009.146"},{"doi-asserted-by":"publisher","key":"e_1_2_7_27_1","DOI":"10.1016\/j.jbspin.2007.10.011"},{"doi-asserted-by":"publisher","key":"e_1_2_7_28_1","DOI":"10.1086\/598331"},{"doi-asserted-by":"publisher","key":"e_1_2_7_29_1","DOI":"10.1111\/jdv.12307"},{"doi-asserted-by":"publisher","key":"e_1_2_7_30_1","DOI":"10.1038\/sj.jidsymp.5650032"},{"issue":"3","key":"e_1_2_7_31_1","first-page":"381","article-title":"Inhibition of varicella\u2010zoster virus in vitro by human peripheral blood mononuclear cells","volume":"75","author":"Rabalais GP","year":"1989","journal-title":"Clin Exp Immunol"},{"doi-asserted-by":"publisher","key":"e_1_2_7_32_1","DOI":"10.1002\/jmv.1890390312"},{"doi-asserted-by":"publisher","key":"e_1_2_7_33_1","DOI":"10.1371\/journal.pone.0193299"},{"doi-asserted-by":"publisher","key":"e_1_2_7_34_1","DOI":"10.1016\/j.semarthrit.2005.01.004"},{"doi-asserted-by":"publisher","key":"e_1_2_7_35_1","DOI":"10.1016\/j.pharmthera.2007.10.001"},{"doi-asserted-by":"publisher","key":"e_1_2_7_36_1","DOI":"10.1002\/art.10302"},{"doi-asserted-by":"publisher","key":"e_1_2_7_37_1","DOI":"10.1016\/j.cgh.2006.09.019"},{"doi-asserted-by":"publisher","key":"e_1_2_7_38_1","DOI":"10.1016\/j.jaad.2015.12.059"},{"doi-asserted-by":"publisher","key":"e_1_2_7_39_1","DOI":"10.1136\/ard.2008.089276"},{"doi-asserted-by":"publisher","key":"e_1_2_7_40_1","DOI":"10.1136\/annrheumdis-2013-205148"},{"doi-asserted-by":"publisher","key":"e_1_2_7_41_1","DOI":"10.1016\/j.ijid.2017.04.016"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.13694","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13694","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1756-185X.13694","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T16:33:13Z","timestamp":1694104393000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1111\/1756-185X.13694"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13694","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"type":"print","value":"1756-1841"},{"type":"electronic","value":"1756-185X"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"assertion":[{"value":"2019-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}